Tidagixagene derxeparvovec

德哌替达基

Report date: 2024/05/30 09:24:42

Base Information

Drug NameTidagixagene derxeparvovec
Drug Alias Nameself-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsidTSHA-120TSHA 120
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionGigaxonin gene transference
TargetsGigaxonin
Therapy Area/IndicationsGiant Axonal Neuropathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTaysha Gene Therapies Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstellas Gene Therapies IncAstellas Pharma IncTaysha Gene Therapies Inc
Active IndicationsN/A
Inactive IndicationsGiant Axonal Neuropathy

Other Information

ATC CodeN/A
Related LinksN/A